OIPE
APR 13 2001
PATENT & TRADEMARK OFFICE

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

# INFORMATION DISCLOSURE STATEMENT

*(Use several sheets if necessary)*

| Atty. Docket No. | Serial No. |
|---|---|
| 29841/36636 | 09/601,667 |
| **Applicant** | |
| Morris et al. | |
| **Filing Date** | **Group** |
| 10/06/00 | To be assigned |

## U.S. PATENT DOCUMENTS

| *Examiner Initials | | Document Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
|---|---|---|---|---|---|---|---|
| SWL | A1 | 5,091,309 A | 02/25/92 | Schlesinger et al. | 435 | 69.1 | |

## FOREIGN PATENT DOCUMENTS

| *Examiner Initials | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes | Translation No |
|---|---|---|---|---|---|---|---|---|
| SWL | B1 | EP 0751211 A | 01/02/97 | EP | | | X (abstract only) | |
| SWL | B2 | EP 0884388 A | 12/16/98 | EP | | | X (abstract only) | |
| SWL | B3 | WO 96/21458 | 07/18/96 | FI | | | X | |
| SWL | B4 | WO 98/29540 | 07/09/98 | DE | | | X | |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|---|---|---|
| SWL | C1 | Beuth et al., *Arzeim-Forsch./Drug.Res.*, (43)166-169(1993). |
| SWL | C2 | Beuth et al., *Arzeim-Forsch./Drug.Res.*, (45)1240-1242(1995). |
| SWL | C3 | Beuth et al., *Clin. Investing*, (70)658-661(1992). |
| SWL | C4 | Beuth et al., *In Vivo*, (5)29-32(1991). |
| SWL | C5 | Beuth et al., *In Vivo*, (7)407-410(1993). |
| SWL | C6 | Beuth et al., *In Vivo*, (8)989-992(1994). |

EXAMINER Sandra — DATE CONSIDERED 4-1-2003

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

SHEET 2 of 3

| Atty. Docket No. | Serial No. |
|---|---|
| 29841/36636 | 09/601,667 |
| Applicant: Morris et al. | |
| Filing Date: 10/06/00 | Group: To be assigned |

# INFORMATION DISCLOSURE STATEMENT

*(Use several sheets if necessary)*

OIPE JC133 APR 13 2001 PATENT & TRADEMARK OFFICE

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | |
|---|---|---|
| SWL | C7 | Beuth et al., *Med. Welt,* (44)217-220(1993). |
| SWL | C8 | Falconer et al., *J. Endrocrinol.*, (118)5-8(1988). |
| SWL | C9 | Gabius et al., "The Immunomodulatory Beta-Galactoside-Specific Lectin fom Mistletoe: Partial Sequence Analysis, Cell and Tissue Binding, and Impact on Intracellular Biosignalling of Monocytic Leukemia Cells", *Anticancer Research,* (12:3)669-676(1992). |
| SWL | C10 | Hajto et al., *Cancer Res.*, (50)3322-3326(1990). |
| SWL | C11 | Harris et al., "Strategies for Targeted Gene Therapy", *Trends in Genetics,* (12:10)400-405(1996). |
| SWL | C12 | Heiny et al., *Anticancer Res.*, (14)1339-1342(1994). |
| SWL | C13 | Huguet et al., "Complete Amino Acid Sequence if the A-Chain of Mistletoe Lectin I", *FEBS Letters,* (399)153-157(1996). |
| SWL | C14 | Huguet et al., "Complete Amino Acid Sequence if the B-Chain of Mistletoe Lectin I", *Biochemical and Biophysical Reasearch Communications,* (246:3)596-601(1998). |
| SWL | C15 | Grabherr et al., *Biotechnics,* (22)730-735(1997). |
| SWL | C16 | Joelson et al., *Journal of General Virology,* (78)1213-1217(1997). |
| SWL | C17 | Kayser et al., *Tumordiag.und Ther., (13)190-195(1992).* |
| SWL | C18 | Kumagai et al., *Proc. Natl. Acad. Sci. USA,* (90)427-430(1993). |
| SWL | C19 | Luther et al., *Int. J. Biochem.*, (11)429-435(1980). |
| SWL | C20 | Macindoe et al., *Carbohydrate Research,* (269:2)227-257(1995). |
| SWL | C21 | Meynial-Salles et al., *J. Biotechnol.*, 46(1)1-14(1996). |
| SWL | C22 | Miller et al., *Human Gene Therapy,* (8)803-815(1997). |
| SWL | C23 | Nickrent et al., *American Journal of Botany,* (81)1149-1160(1994). |

| EXAMINER | DATE CONSIDERED |
|---|---|
| [signature] | 4-1-2003 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC13
APR 13 2001
PATENT & TRADEMARK OFFICE



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

# INFORMATION DISCLOSURE STATEMENT

*(Use several sheets if necessary)*

| Atty. Docket No. | Serial No. |
|---|---|
| 29841/36636 | 09/601,667 |
| **Applicant** | |
| Morris et al. | |
| **Filing Date** | **Group** |
| 10/06/00 | To be assigned |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | |
|---|---|---|
| SWL | C24 | Paprocka et al., "The Activity if Two Immunotoxins Composed of Monoclonal Antibody MOAB-16 and A-Chain of Ricin(MOAB-16-MLIA) or A-Chain of Mistletoe Lectini(MOAB-16-MLIA)", *Archivum Immunologiae et Therapiae Experimentalis*, 40(3)223-227(1992). |
| SWL | C25 | Schink et al., *Naturwissenschaften*, (79)80-81(1992). |
| SWL | C26 | Storm et al., *Hybridoma*, (16)119-125(1997). |
| SWL | C27 | Thierry et al., *Gene Therapy*, (4)226-237(1997). |
| SWL | C28 | Walter et al., *Molecular Biotechnology*, (6)267-286(1996). |
| SWL | C29 | Wong, S.Y., *Current Opinion in Structural Biology*, 5(5)599-604(1995). |

| EXAMINER | DATE CONSIDERED |
|---|---|
| | 4-1-2003 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.